183 related articles for article (PubMed ID: 26040057)
1. Autoimmune hepatitis triggered by adalimumab and allergic reactions after various anti-TNFα therapy agents in a patient with rheumatoid arthritis.
Petríková J; Jarčuška P; Svajdler M; Pella D; Macejová Z
Isr Med Assoc J; 2015 Apr; 17(4):256-8. PubMed ID: 26040057
[No Abstract] [Full Text] [Related]
2. A case of eczematous and vesicular dermatitis during anti-TNFalpha therapy for rheumatoid arthritis.
Savoia F; Gaddoni G; Casadio C; Spadola G; Patrizi A; Giacomini F; Aldi M
G Ital Dermatol Venereol; 2011 Aug; 146(4):308-9. PubMed ID: 21785399
[No Abstract] [Full Text] [Related]
3. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
[No Abstract] [Full Text] [Related]
4. [TNF inhibitors for treatment of rheumatoid arthritis].
Otomo K; Koike T
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2405-12. PubMed ID: 19149036
[No Abstract] [Full Text] [Related]
5. [TNFalpha inhibitors for the treatment of rheumatoid arthritis].
Sany J; Kaiser MJ
Ann Med Interne (Paris); 2002 Feb; 153(1):34-40. PubMed ID: 11994688
[TBL] [Abstract][Full Text] [Related]
6. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
[TBL] [Abstract][Full Text] [Related]
7. [Proper usage of biologics for treatment of rheumatoid arthritis].
Murayama M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):894-8. PubMed ID: 19469085
[No Abstract] [Full Text] [Related]
8. Vaccine history knowledge of subcutaneous anti-TNF receiving rheumatology patients.
Nolan TJ; O'Connor MB; Bond U; Swan J; Phelan MJ
Rheumatol Int; 2013 Jul; 33(7):1907-8. PubMed ID: 22441967
[No Abstract] [Full Text] [Related]
9. [Rheumatoid arthritis: current status of therapy].
El Bahri DM; Meddeb N; Sellami S
Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
Gabriel SE
Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805
[No Abstract] [Full Text] [Related]
11. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept.
Grasland A; Sterpu R; Boussoukaya S; Mahe I
Eur J Clin Pharmacol; 2012 May; 68(5):895-8. PubMed ID: 22205272
[No Abstract] [Full Text] [Related]
12. New drugs for rheumatoid arthritis.
Olsen NJ; Stein CM
N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
[No Abstract] [Full Text] [Related]
13. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register.
Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2012 Nov; 64(11):3502-10. PubMed ID: 22886739
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
[TBL] [Abstract][Full Text] [Related]
15. Multiple eruptive plaque-like dermatofibromas during anti-TNFα treatment.
Caldarola G; Bisceglia M; Pellicano R
Int J Dermatol; 2013 May; 52(5):638-41. PubMed ID: 22804251
[No Abstract] [Full Text] [Related]
16. A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C.
Chen YM; Chen HH; Chen YH; Hsieh TY; Hsieh CW; Hung WT; Lan JL; Chen DY
Ann Rheum Dis; 2015 Mar; 74(3):626-7. PubMed ID: 25452310
[No Abstract] [Full Text] [Related]
17. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry.
Serac G; Tubach F; Mariette X; Salmon-Céron D; Ravaud P; Lioté F; Laharie D; Ziza JM; Marguerie L; Bonnet C; Falgarone G; Nicolas N; Lortholary O; Chosidow O
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):726-9. PubMed ID: 22113472
[No Abstract] [Full Text] [Related]
18. Autoimmune hepatitis and allergic reactions during anti-TNFα treatment.
Atzeni F; Sarzi-Puttini P
Isr Med Assoc J; 2015 Apr; 17(4):247-8. PubMed ID: 26040053
[No Abstract] [Full Text] [Related]
19. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
20. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
